GlassScriptPhysician profile
Eugene Charles Fortune
NPI 1669905329
$1,955.29
in general payments reported to CMS, 2019-2025
15 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $108 · 2023: $1,239 · 2024: $427 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,175 · Travel and Lodging: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,175.03 |
| Travel and Lodging | $672.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,048.80 | 2022-2025 | Spaceoar Vue System - 10ml, Spaceoar System |
| Merck Sharp & Dohme LLC | $293.81 | 2022-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Sumitomo Pharma America, INC. | $254.90 | 2023-2025 | Orgovyx |
| Neurocrine Biosciences, INC. | $119.60 | 2024 | Ingrezza |
| Stryker Corporation | $39.69 | 2023 | Spinejack |
| Novartis Pharmaceuticals Corporation | $31.87 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $28.67 | 2024 | Calquence, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $21.39 | 2025 | Iclusig |
| Myovant Sciences INC. | $19.86 | 2022 | |
| Geron Corporation | $18.79 | 2025 | Rytelo |
| Sobi, INC | $18.58 | 2024 | |
| Pfizer INC. | $16.17 | 2024 | |
| Beigene USA, INC. | $15.88 | 2022 | |
| Telix Pharmaceuticals | $14.38 | 2022 | |
| Seagen INC. | $12.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Fortune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.